Länder Analysen: Schweiz

03.04.24 Givaudan Sell UBS AG
02.04.24 Givaudan Underweight Barclays Capital
02.04.24 DocMorris Sell UBS AG
28.03.24 Novartis Underweight Barclays Capital
25.03.24 Nestlé Underperform Jefferies & Company Inc.
21.03.24 DocMorris Sell UBS AG
20.03.24 Givaudan Underweight Barclays Capital
13.03.24 Swiss Re Sell UBS AG
23.02.24 Zurich Insurance Verkaufen DZ BANK
23.02.24 Zurich Insurance Underweight JP Morgan Chase & Co.
22.02.24 Nestlé Underperform RBC Capital Markets
22.02.24 Nestlé Underperform Jefferies & Company Inc.
22.02.24 Zurich Insurance Underweight JP Morgan Chase & Co.
19.02.24 Swiss Re Sell UBS AG
16.02.24 Swiss Re Sell UBS AG
13.02.24 DocMorris Sell UBS AG
09.02.24 UBS Underweight Barclays Capital
06.02.24 Novartis Underweight Barclays Capital
06.02.24 UBS Underweight Barclays Capital
29.01.24 Givaudan Underweight Barclays Capital
26.01.24 Givaudan Sell UBS AG
25.01.24 Zurich Insurance Underweight JP Morgan Chase & Co.
25.01.24 Givaudan Underperform Jefferies & Company Inc.
25.01.24 Givaudan Sell UBS AG
19.01.24 UBS Underweight Barclays Capital
17.01.24 Swiss Re Sell UBS AG
16.01.24 DocMorris Sell UBS AG
11.01.24 Givaudan Underperform Jefferies & Company Inc.
21.12.23 Novartis Underweight Barclays Capital
19.12.23 Givaudan Underweight Barclays Capital
19.12.23 Swiss Re Sell UBS AG
19.12.23 Givaudan Sell UBS AG
13.12.23 Givaudan Sell UBS AG
12.12.23 Nestlé Underperform RBC Capital Markets
12.12.23 Givaudan Underperform Jefferies & Company Inc.
10.12.23 Nestlé Underperform Jefferies & Company Inc.
06.12.23 Swiss Re Sell UBS AG
06.12.23 Zurich Insurance Underweight JP Morgan Chase & Co.
01.12.23 Swiss Re Sell UBS AG
29.11.23 Novartis Underweight Barclays Capital
28.11.23 Givaudan Underperform Bernstein Research
20.11.23 Givaudan Sell UBS AG
14.11.23 DocMorris Sell UBS AG
14.11.23 Swiss Re Sell UBS AG
09.11.23 Zurich Insurance Underweight JP Morgan Chase & Co.
07.11.23 UBS Underweight Barclays Capital
06.11.23 Swiss Re Sell UBS AG
03.11.23 Swiss Re Sell UBS AG
30.10.23 Givaudan Sell UBS AG
23.10.23 Novartis Underweight Barclays Capital